Sign Out
OVERDOSE AND TREATMENT: Overdose data are limited.
After administration of bilastine at dose 10-11 times the therapeutic dose to healthy volunteers frequency of treatment emergent adverse events was two times higher than with placebo. The adverse reactions most frequently reported were dizziness, headache and nausea. No serious adverse events and no significant prolongation in the QTc interval were reported.
Symptomatic and supportive treatment is recommended.
Continue with Google